On 2 November 2026, China's state broadcaster CCTV published a data-led summary of the country's birth-support spending under the headline 1010亿元，惠及3355万人次！"数"说生育保障更有温度、更有品质. Two numbers carry the story: a total of 101 billion yuan paid out, reaching 33.55 million person-times. If you are weighing fertility treatment in China as a self-paying visitor, that headline is not about you — no part of that pool can be claimed from outside the domestic insurance system. It is still worth reading carefully, because it tells you which procedures China's payer has decided to fund, and therefore which procedures have a public, itemised price rather than a marketing one. That is the difference between an IVF cost you can compare and an IVF cost you simply have to trust.
What the national numbers do — and do not — tell an overseas patient
The CCTV report is a national aggregate. In checking it, only the two headline figures in the title were reliably available to us; the item-level breakdown behind the 101 billion yuan was not, so we are not repeating one here. Two limits follow from that.
First, the total covers maternity protection broadly understood — antenatal and delivery care, maternity allowance, and assisted-reproduction benefits where a province has added them. It is not a standalone statistic for in-vitro fertilisation. Second, it is expressed in yuan and should be converted at the day's exchange rate rather than a number someone quoted you months ago.
What the figure does establish is direction. A payout measured in hundreds of billions of yuan and tens of millions of person-times means the payment side of obstetrics and assisted reproduction in China is institutionalised and expanding, with provincial medical-insurance bureaus adding laboratory procedures to reimbursable catalogues. Where a payer sets prices, itemised listings tend to become public. Where a payer is absent — which is your situation as an international patient — those same listings become the most honest reference point available for judging whether a self-pay quotation is reasonable.
Jilin's October notice is the most useful price anchor published this month
One week before the CCTV report, Jilin's medical-insurance bureau, finance department and tax bureau jointly issued the notice 《关于完善生育保障有关政策的通知》 (吉医保规〔2026〕3号), signed 27 October 2026, with each pooling area required to implement it by the end of December 2026 (吉林省：生育新政落地！). Read as a document about what has a price, it is unusually concrete.
The procedures already inside Jilin's medical-insurance payment scope for assisted reproduction are egg retrieval, embryo culture, embryo transfer, tissue and cell biopsy for assisted reproduction, artificial insemination, sperm optimisation, sperm retrieval, and single-sperm injection (ICSI). Outpatient costs falling within the policy are reimbursed at the outpatient special-disease rate, and the basic medical-insurance fund will pay for these treatments a maximum of three times per person. Two items — sperm retrieval and sperm optimisation — carry no deductible at all.
On the maternity side, the notice sets maternity insurance with no deductible threshold, reimburses policy-scope medical costs at 100 percent, and caps payment at no more than 16,000 yuan within one birth cycle. The payable amount is released progressively: 30 percent in the first trimester, 50 percent in the second, 70 percent in the third, and 100 percent at delivery and postpartum. For people in flexible employment or receiving unemployment insurance, the maternity allowance is assessed at 98 days; claiming it requires twelve consecutive months of enrolment in employee medical insurance including maternity cover, and processing takes ten working days from application. The notice also states that giving birth under the service permit or a marriage certificate cannot be demanded.
Here is the boundary line that matters for you. This is a provincial employee and resident benefit. It is not an international package, and a non-insured visitor cannot enrol retroactively to obtain it. Two very different people read this document differently: a foreign national employed in Jilin and covered by Chinese social insurance has a genuinely lower out-of-pocket exposure, because eight named laboratory procedures now have a reimbursement pathway. A patient flying in has none of that, but gains something else — a dated, official list of the components of an IVF cycle, which is exactly the list you should demand when you ask for a quotation.
How to read the cost of IVF in China as a self-paying patient
Ask for the cycle split into the same parts the notice uses
Chinese clinic quotations are usually given either as a package total or as a per-item list. The safest approach is to require both, and to check they reconcile. Take the Jilin list as your template and ask where each of these sits in the price, and whether it is inside or outside:
- Initial consultation and the physician's proposed protocol
- Baseline and stimulation monitoring: ultrasound scans and hormone assays, counted per visit
- Trigger injection and the egg-retrieval procedure, including anaesthesia
- Embryology: culture, ICSI if needed, and any biopsy for genetic testing
- Embryo transfer, and the number of transfers included
- Freezing, and the annual storage fee after year one
- Medication, which is frequently quoted separately because the dose is not known in advance
The line items that most often move a bill are medication, monitoring visits beyond the planned number, genetic testing on embryos, and storage. None of these should be a surprise if they are named in writing before the first injection.
Then compare routes, not headlines
| Payment route | Who can use it | What sets the price | Published, verifiable numbers | How an overseas patient should treat it |
|---|---|---|---|---|
| Jilin insured pathway (maternity cover plus assisted-reproduction outpatient items) | People enrolled in a Jilin pooling area's basic medical insurance, foreign employees included | Policy catalogue and fund rules | 100% reimbursement of policy-scope maternity costs, cap no higher than 16,000 yuan per birth cycle; ART funded up to 3 sessions per person; no deductible on sperm retrieval and sperm optimisation | Relevant only if you are locally insured. Check your status with the bureau, not with an agent |
| Self-pay at a mainland reproductive centre | Any patient the centre accepts and can schedule | The centre's own price list, per item or as a package | None quoted here. Request the written list | This is where a materially lower nominal price than most high-income markets is claimed. Verify it against an itemised, dated quotation |
| International or VIP service setting | Same patients, with language and coordination support included | A service bundle on top of clinical items | None published | Expect numbers closer to home-market pricing. Ask explicitly what the service premium buys |
| Self-pay cycle in your home market | Local patients | Published clinic pricing and private insurer rules | Widely reported in the tens of thousands of US dollars per cycle | Compare line-for-line against the Chinese item list, not total against total |
The comparison only holds if you keep the clinical scope identical. A quoted "cycle" that excludes medication and storage is not a cheaper cycle; it is a narrower one.
Where the timeline enters the bill
A stimulated cycle is built around monitoring, so the calendar and the invoice are the same document. Ask how many on-site days the monitoring schedule requires, what happens if follicle response moves the retrieval date, whether a fresh transfer is possible on your travel window or whether the plan is freeze-all, and what the cost of an additional cycle would be if the first is not usable. Age and diagnosis drive how many cycles a patient realistically faces, which is why per-cycle pricing and per-add-on pricing matter more than any published success claim. We do not present success rates here, and you should treat any clinic-supplied rate as advertising until you can see the cohort it came from.
The non-clinical costs are yours to plan
Budget separately for the medical visit visa and supporting documents — our China medical visa guide covers the application route — for lodging near the centre across the monitoring window, for certified translation of your prior cycles and laboratory reports, and for the rules on carrying medication home. Arrange hospital booking and on-the-ground coordination through our appointment service rather than improvising once you arrive, since a cycle calendar cannot absorb a scheduling failure. Some patients also ask about complementary care during the same trip; that is a separate consultation with its own pricing, described on our Traditional Chinese Medicine services in Shanghai page, and it must be disclosed to the reproductive physician before anything is started. Broader context on choosing China as a treatment destination is in our complete medical tourism guide, and you can see the institution types involved under Hospitals.
Before you commit to anything, get the records review done first. A physician has to see your age, ovarian reserve findings, semen analysis, prior retrieval and transfer reports, and any uterine history before a protocol — and therefore a defensible cost — exists. 具体治疗方案需由执业医师面诊评估: any treatment plan, and the quotation that follows it, must be assessed in person by a licensed physician. Costs in this article that are not attributed to the CCTV or Jilin documents are not estimates; they are questions for the centre.
OriEast can help on both sides of that line — translating and structuring your medical records for review, booking the appointment, itemising and reconciling the quotation you receive, and coordinating interpretation, travel logistics and follow-up while you are in China. Send your case through our case evaluation form to get a physician-led read on whether treatment in China is appropriate for you, or open a direct inquiry and we will respond with the specific documents and cost breakdown you need to ask for.